CBM - Cambrex Corporation

NYSE - NYSE Delayed Price. Currency in USD
42.87
-1.10 (-2.50%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close 43.97
Open 43.99
Bid 43.03 x 800
Ask 47.00 x 800
Day's Range 42.85 - 44.22
52 Week Range 33.80 - 69.43
Volume 116,985
Avg. Volume 232,933
Market Cap 1.443B
Beta (3Y Monthly) 2.22
PE Ratio (TTM) 18.34
EPS (TTM) 2.34
Earnings Date Jul 31, 2019 - Aug 5, 2019
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date 2007-05-04
1y Target Est 49.20
Trade prices are not sourced from all markets
  • Calculating The Fair Value Of Cambrex Corporation (NYSE:CBM)
    Simply Wall St. 5 days ago

    Calculating The Fair Value Of Cambrex Corporation (NYSE:CBM)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Cambrex Corporation...

  • Markit 6 days ago

    See what the IHS Markit Score report has to say about Cambrex Corp.

    Cambrex Corp NYSE:CBMView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for CBM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CBM had net inflows of $924 million over the last one-month. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Basic Materials sector is rising. The rate of growth is weak relative to the trend shown over the past year, but is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • CBM vs. ALKS: Which Stock Should Value Investors Buy Now?
    Zacks 11 days ago

    CBM vs. ALKS: Which Stock Should Value Investors Buy Now?

    CBM vs. ALKS: Which Stock Is the Better Value Option?

  • GlobeNewswire 13 days ago

    Cambrex Completes New Process and Analytical Development Facility at its Karlskoga, Sweden Manufacturing Site

    Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed a new 600 m2 facility at its site in Karlskoga, Sweden, which incorporates new laboratories for process and analytical development. The new, three-story building will incorporate process technology, QC and analytical development laboratories. The process technology laboratories will expand capacity providing an area where R&D and production teams can work together on scale up demonstration and technology transfer, including new capabilities in the scaling up of potent molecules requiring containment.  The facility will employ computer modeling to optimize reactor set ups and plant conditions to improve technology transfer and the performance of existing processes.

  • GlobeNewswire 19 days ago

    Cambrex to Present at Upcoming Investor Conferences in June

    EAST RUTHERFORD, N.J., May 29, 2019 -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across.

  • The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
    Zacks 25 days ago

    The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

    The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology

  • 5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
    Zacks 26 days ago

    5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon

    Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.

  • CBM vs. TECH: Which Stock Is the Better Value Option?
    Zacks 27 days ago

    CBM vs. TECH: Which Stock Is the Better Value Option?

    CBM vs. TECH: Which Stock Is the Better Value Option?

  • Thomson Reuters StreetEvents last month

    Edited Transcript of CBM earnings conference call or presentation 2-May-19 12:30pm GMT

    Q1 2019 Cambrex Corp Earnings Call

  • Can Cambrex (CBM) Run Higher on Rising Earnings Estimates?
    Zacks last month

    Can Cambrex (CBM) Run Higher on Rising Earnings Estimates?

    Cambrex (CBM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

  • Cambrex (CBM) Surpasses Q1 Earnings Estimates
    Zacks 2 months ago

    Cambrex (CBM) Surpasses Q1 Earnings Estimates

    Cambrex (CBM) delivered earnings and revenue surprises of 17.65% and -0.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press 2 months ago

    Cambrex: 1Q Earnings Snapshot

    The East Rutherford, New Jersey-based company said it had net income of 31 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, came to 60 cents per share. The results ...

  • GlobeNewswire 2 months ago

    Cambrex Reports First Quarter 2019 Financial Results

    - Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base - - Reaffirms full year financial guidance - - Conference.

  • GlobeNewswire 2 months ago

    Cambrex to Announce First Quarter 2019 Financial Results on May 2, 2019

    EAST RUTHERFORD, N.J., April 30, 2019 -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services.

  • Cambrex (CBM) to Report Q1 Results: Wall Street Expects Earnings Growth
    Zacks 2 months ago

    Cambrex (CBM) to Report Q1 Results: Wall Street Expects Earnings Growth

    Cambrex (CBM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire 2 months ago

    Cambrex Completes New Quality Control Laboratory for Generic API Development in Milan

    Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had opened a new 120m2 quality control (QC) laboratory at its site in Paullo, Milan, Italy. The laboratory expands on the current QC facilities that analyze and test its generic API portfolio of products during development and manufacturing. The QC laboratory is now fully operational, having been authorized by the Agenzia Italiana Del Farmaco (AIFA).

  • Update: Cambrex (NYSE:CBM) Stock Gained 80% In The Last Five Years
    Simply Wall St. 2 months ago

    Update: Cambrex (NYSE:CBM) Stock Gained 80% In The Last Five Years

    Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. For example, long term Ca...

  • GlobeNewswire 2 months ago

    Cambrex Completes Highly Potent API Manufacturing Facility at Charles City, IA

    Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had completed the construction of a $24 million highly potent API (HPAPI) manufacturing facility at its site in Charles City, IA. The production area will operate to an occupational exposure limit (OEL) down to 0.1µg/m3 and contain 4 reactors ranging from 200 to 1,000 gallon capacity enabling manufacturing campaigns of batch sizes up to 300 kg. With the completion of this new facility, the Charles City site now has the flexibility to support all phases of development and offer all scales of HPAPI manufacture across the full OEL band spectrum.

  • GlobeNewswire 3 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within Nutanix, Steel Dynamics, Audentes Therapeutics, Comfort Systems, LHC Group, and Cambrex — New Research Emphasizes Economic Growth

    NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire 3 months ago

    Cambrex Doubles cGMP Liquid Filling Capacity at its Mirabel, Québec Facility

    EAST RUTHERFORD, N.J., March 26, 2019 -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services.